Lv4
432 积分 2026-03-30 加入
20Phase II trial of ivonescimab in patients with advanced clear cell renal cell carcinoma previously treated with immune checkpoint blockade: IVORY trial (NCT06940518)
2个月前
已关闭
Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR‐mutant nonsmall cell lung cancer with brain metastasis
2个月前
已完结
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
2个月前
已完结
OA09.06 IMpower151: Phase III Study of Atezolizumab + Bevacizumab + Chemotherapy in 1L Metastatic Nonsquamous NSCLC
2个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
2个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
2个月前
已完结
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
2个月前
已完结
New promises and challenges in the treatment of advanced non-small-cell lung cancer
2个月前
已完结
Ivonescimab: First Approval
2个月前
已完结
The next generation of immunotherapies for lung cancers
2个月前
已完结
皖公网安备34019202002308
